$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

$apls Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024020614 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$172.3M	$146.4M	$396.6M
YoY Change	284.26%	545.89%	425.83%
Cost Of Revenue	$20.21M	$19.91M	$58.51M
YoY Change	158.79%	580.75%	938.15%
Gross Profit	$152.1M	$126.5M	$338.1M
YoY Change	310.71%	540.72%	384.45%
Gross Profit Margin	88.27%	86.4%	85.25%
Selling, General & Admin	$129.5M	$141.7M	$500.8M
YoY Change	26.85%	67.96%	80.69%
% of Gross Profit	85.14%	112.05%	148.13%
Research & Development	$84.70M	$69.28M	$354.4M
YoY Change	-23.02%	-30.32%	-8.48%
% of Gross Profit	55.68%	54.78%	104.82%
Depreciation & Amortization	$444.0K	$476.0K	$1.784M
YoY Change	5.46%	22.68%	14.95%
% of Gross Profit	0.29%	0.38%	0.53%
Operating Expenses	$234.4M	$211.0M	$913.7M
YoY Change	6.59%	14.8%	36.37%
Operating Profit	-$62.09M	-$84.52M	-$517.1M
YoY Change	-64.54%	-48.48%	-13.03%
Interest Expense	-$3.664M	-$2.854M	-$8.648M
YoY Change	71.54%	-9.77%	-63.53%
% of Operating Profit
Other Income/Expense, Net	-$499.0K	$219.0K	-$727.0K
YoY Change	80.14%	-189.02%	152.43%
Pretax Income	-$66.25M	-$87.15M	-$526.5M
YoY Change	-62.67%	-47.96%	-19.19%
Income Tax	$200.0K	$1.423M	$2.132M
% Of Pretax Income
Net Earnings	-$66.42M	-$88.58M	-$528.6M
YoY Change	-62.64%	-46.64%	-18.94%
Net Earnings / Revenue	-38.55%	-60.51%	-133.29%
Basic Earnings Per Share	-$0.54		-$4.45
Diluted Earnings Per Share	-$0.54	-$0.73	-$4.45
COMMON SHARES
Basic Shares Outstanding	120.6M	118.5M	118.7M
Diluted Shares Outstanding	123.0K		118.7M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$325.9M	$351.2M	$351.2M
YoY Change	-57.4%	-36.36%	-36.36%
Cash & Equivalents	$325.9M	$351.2M	$351.2M
Short-Term Investments
Other Short-Term Assets	$12.12M	$22.41M	$44.29M
YoY Change	-64.72%	-38.87%	-16.18%
Inventory	$161.3M	$146.4M	$146.4M
Prepaid Expenses	$43.16M	$38.82M
Receivables	$267.8M	$206.4M	$206.4M
Other Receivables	$4.499M	$18.05M	$18.05M
Total Short-Term Assets	$811.4M	$766.3M	$766.3M
YoY Change	-14.97%	6.51%	6.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.195M	$4.345M	$21.09M
YoY Change	-29.7%	-29.33%	-15.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.313M	$1.309M	$1.309M
YoY Change	65.57%	-91.71%	-91.71%
Total Long-Term Assets	$20.50M	$22.40M	$22.40M
YoY Change	-16.71%	-44.96%	-44.96%
TOTAL ASSETS
Total Short-Term Assets	$811.4M	$766.3M	$766.3M
Total Long-Term Assets	$20.50M	$22.40M	$22.40M
Total Assets	$831.9M	$788.7M	$788.7M
YoY Change	-15.01%	3.75%	3.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.79M	$37.52M	$37.52M
YoY Change	-14.94%	0.47%	0.47%
Accrued Expenses	$101.4M	$127.8M	$134.2M
YoY Change	42.31%	34.34%	33.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$77.29M	$75.83M	$75.83M
YoY Change	157.02%	157.02%	157.02%
Total Short-Term Liabilities	$215.3M	$247.6M	$247.6M
YoY Change	55.28%	47.72%	47.72%
LONG-TERM LIABILITIES
Long-Term Debt	$337.5M	$332.9M	$332.9M
YoY Change	-18.57%	-18.5%	-18.5%
Other Long-Term Liabilities	$2.658M	$2.312M	$13.77M
YoY Change	665.99%	-83.89%	-4.08%
Total Long-Term Liabilities	$2.658M	$2.312M	$346.6M
YoY Change	665.99%	-99.45%	-18.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$215.3M	$247.6M	$247.6M
Total Long-Term Liabilities	$2.658M	$2.312M	$346.6M
Total Liabilities	$565.3M	$594.2M	$594.2M
YoY Change	-0.26%	0.65%	0.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.900B	-$2.800B
YoY Change	16.0%	21.74%
Common Stock	$12.00K	$12.00K
YoY Change	0.0%	9.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$266.7M	$194.5M	$194.5M
YoY Change
Total Liabilities & Shareholders Equity	$831.9M	$788.7M	$788.7M
YoY Change	-15.01%	3.75%	3.75%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$66.42M	-$88.58M	-$528.6M
YoY Change	-62.64%	-46.64%	-18.94%
Depreciation, Depletion And Amortization	$444.0K	$476.0K	$1.784M
YoY Change	5.46%	22.68%	14.95%
Cash From Operating Activities	-$133.0M	-$97.88M	-$594.7M
YoY Change	-25.13%	-30.46%	15.76%
INVESTING ACTIVITIES
Capital Expenditures	$293.0K	$95.00K	$773.0K
YoY Change	13.13%	-88.84%	-49.28%
Acquisitions
YoY Change
Other Investing Activities		$99.00K	$99.00K
YoY Change		-99.92%	-99.84%
Cash From Investing Activities	-$293.0K	$4.000K	-$674.0K
YoY Change	13.13%	-100.0%	-101.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	108.2M	-3.913M	394.5M
YoY Change	-72.33%	-75.46%	7.89%
NET CHANGE
Cash From Operating Activities	-133.0M	-97.88M	-594.7M
Cash From Investing Activities	-293.0K	4.000K	-674.0K
Cash From Financing Activities	108.2M	-3.913M	394.5M
Net Change In Cash	-25.27M	-101.8M	-200.8M
YoY Change	-111.85%	212.59%	126.4%
FREE CASH FLOW
Cash From Operating Activities	-$133.0M	-$97.88M	-$594.7M
Capital Expenditures	$293.0K	$95.00K	$773.0K
Free Cash Flow	-$133.3M	-$97.97M	-$595.5M
YoY Change	-25.07%	-30.81%	15.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001492422
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2022	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2021	us-gaap	Defined Contribution Plan Tax Status Extensible List DefinedContributionPlanTaxStatusExtensibleList	http://fasb.org/us-gaap/2023#QualifiedPlanMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38276
CY2023	dei	Entity Registrant Name EntityRegistrantName	APELLIS PHARMACEUTICALS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1537290
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Fifth Avenue
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02451
CY2023	dei	City Area Code CityAreaCode	617
CY2023	dei	Local Phone Number LocalPhoneNumber	977-5700
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	APLS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	10700000000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	120581749
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351185000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	551801000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	206442000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7727000
CY2023Q4	us-gaap	Inventory Net InventoryNet	146362000
CY2022Q4	us-gaap	Inventory Net InventoryNet	85714000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38820000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36350000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1114000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1273000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	22408000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	36658000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	766331000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	719523000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16745000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18747000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4345000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6148000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1309000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15799000
CY2023Q4	us-gaap	Assets Assets	788730000
CY2022Q4	us-gaap	Assets Assets	760217000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	37516000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	37342000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127806000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95139000
CY2023Q4	apls	Development Liability Current DevelopmentLiabilityCurrent	75830000
CY2022Q4	apls	Development Liability Current DevelopmentLiabilityCurrent	29504000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6441000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5625000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	247593000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	167610000
CY2023Q4	apls	Development Liability Noncurrent DevelopmentLiabilityNoncurrent	239817000
CY2022Q4	apls	Development Liability Noncurrent DevelopmentLiabilityNoncurrent	315647000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	93033000
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	92736000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11454000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14352000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2312000
CY2023Q4	us-gaap	Liabilities Liabilities	594209000
CY2022Q4	us-gaap	Liabilities Liabilities	590345000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	119556000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	119556000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110772000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110772000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3035539000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2479596000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3542000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-875000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2837488000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2308860000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194521000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	169872000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	788730000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	760217000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	396591000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75422000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	66563000
CY2023	apls	Operating Cost Of Sales OperatingCostOfSales	58510000
CY2022	apls	Operating Cost Of Sales OperatingCostOfSales	5636000
CY2021	apls	Operating Cost Of Sales OperatingCostOfSales	200000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	354387000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	387236000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	345869000
CY2021	apls	Cost Of Research Collaboration CostOfResearchCollaboration	75000000
CY2021	apls	License Expense LicenseExpense	5000000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	500815000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	277163000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	176771000
CY2023	us-gaap	Operating Expenses OperatingExpenses	913712000
CY2022	us-gaap	Operating Expenses OperatingExpenses	670035000
CY2021	us-gaap	Operating Expenses OperatingExpenses	602840000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-517121000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-594613000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-536277000
CY2022	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	32890000
CY2021	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97675000
CY2023	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	20933000
CY2022	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	8914000
CY2021	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	418000
CY2023	apls	Interest Expense Nonoperating InterestExpenseNonoperating	29581000
CY2022	apls	Interest Expense Nonoperating InterestExpenseNonoperating	32626000
CY2021	apls	Interest Expense Nonoperating InterestExpenseNonoperating	13241000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-727000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-288000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1362000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-526496000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-651503000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-746002000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2132000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	669000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-528628000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-652172000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax	-2618000
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax	1646000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-49000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-430000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1982000
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2667000
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1215000
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1973000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-531295000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-650957000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-748327000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.45
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.45
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.15
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.84
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.84
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118678000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118678000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106114000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106114000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84421000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84421000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	204557000
CY2021	apls	Accounting Standards Update Description AccountingStandardsUpdateDescription	ASU 2020-06
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	380362000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14691000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	421093000
CY2021	apls	Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	4171000
CY2021	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-1788000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	70667000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2970000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1982000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	198662000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	380120000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	129636000
CY2022	apls	Adjustments To Additional Paid In Capital Forfeiture Of Accrued Interest In Exchange Of Convertible Notes AdjustmentsToAdditionalPaidInCapitalForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	1287000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21483000
CY2022	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-5682000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	91085000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4238000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax	1646000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-652172000
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-430000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	169872000
CY2023	apls	Issuance Of Common Stock And Pre Funded Warrants In Common Stock Offering IssuanceOfCommonStockAndPreFundedWarrantsInCommonStockOffering	384387000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71274000
CY2023	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-11040000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	105945000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5378000
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax	-2618000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-528628000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-49000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	194521000
CY2023	us-gaap	Profit Loss ProfitLoss	-528628000
CY2022	us-gaap	Profit Loss ProfitLoss	-652172000
CY2021	us-gaap	Profit Loss ProfitLoss	-746354000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	105945000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	91085000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	70667000
CY2022	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	32890000
CY2021	apls	Loss On Conversion Of Debt LossOnConversionOfDebt	100589000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97675000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-120000
CY2022	apls	Forfeiture Of Accrued Interest In Exchange Of Convertible Notes ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	1287000
CY2021	apls	Forfeiture Of Accrued Interest In Exchange Of Convertible Notes ForfeitureOfAccruedInterestInExchangeOfConvertibleNotes	4171000
CY2023	us-gaap	Depreciation Depreciation	1784000
CY2022	us-gaap	Depreciation Depreciation	1552000
CY2021	us-gaap	Depreciation Depreciation	1379000
CY2023	apls	Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal	-80000
CY2022	apls	Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal	-65000
CY2021	apls	Operating Lease Right Of Use Asset And Right Of Use Liability Amortization Expense Reversal OperatingLeaseRightOfUseAssetAndRightOfUseLiabilityAmortizationExpenseReversal	113000
CY2023	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	297000
CY2022	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	459000
CY2021	apls	Amortization Of Discounts For Convertible Notes Net Of Financing Costs AmortizationOfDiscountsForConvertibleNotesNetOfFinancingCosts	964000
CY2023	apls	Accretion Of Discount To Development Liability AccretionOfDiscountToDevelopmentLiability	25996000
CY2022	apls	Accretion Of Discount To Development Liability AccretionOfDiscountToDevelopmentLiability	26917000
CY2021	apls	Accretion Of Discount To Development Liability AccretionOfDiscountToDevelopmentLiability	1192000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	198715000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2375000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10103000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	60647000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	69397000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16317000
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1870000
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	11479000
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	13487000
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-14243000
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-32936000
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	40928000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-11700000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17490000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12782000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	170000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	18689000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10487000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	34950000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6312000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10392000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-594735000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-513745000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-563126000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	773000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1524000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1103000
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	99000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	331863000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	171281000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	393280000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	420000000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-674000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	59893000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	247616000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	380120000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	380363000
CY2023	apls	Proceeds From Issuance Of Common Stock Pre Funded Warrant Offering Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockPreFundedWarrantOfferingNetOfIssuanceCosts	384387000
CY2021	apls	Proceeds From Payments For Development Derivative Liability ProceedsFromPaymentsForDevelopmentDerivativeLiability	-4000000
CY2023	apls	Payments For Development Liability PaymentsForDevelopmentLiability	55500000
CY2022	apls	Payments For Development Liability PaymentsForDevelopmentLiability	34500000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	71274000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	205000
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	263000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21483000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14691000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5378000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	4238000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2970000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11040000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	5682000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1788000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	394499000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	365659000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	392236000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135000
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-488000
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2016000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-200775000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-88681000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	74710000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	553074000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	641755000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	567045000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352299000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	553074000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	641755000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351185000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	551801000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	640192000
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	1114000
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	1273000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	1563000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	352299000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	553074000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	641755000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3286000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5003000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10265000
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	4915000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	49000
CY2023	us-gaap	Proceeds From Income Tax Refunds ProceedsFromIncomeTaxRefunds	1759000
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	98086000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	328017000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of Organization and Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Apellis Pharmaceuticals, Inc. (the “Company”) is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was incorporated in September 2009 under the laws of the State of Delaware. The Company’s principal executive offices are located in Waltham, Massachusetts.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to product candidates, business planning, raising capital, developing its product candidates, commercializing EMPAVELI (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (“PNH”) and commercializing SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy secondary to age-related macular degeneration (“GA”).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common in the biotechnology industry including, but not limited to, raising additional capital, development by its competitors of new technological innovations, its ability to successfully complete preclinical and clinical development of product candidates and receive timely regulatory approval of products, market acceptance of the Company’s products, protection of proprietary technology, healthcare cost containment initiatives, and compliance with governmental regulations, including those of the U.S. Food and Drug Administration (“FDA”).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Follow-on Public Offerings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2023, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4,007,936</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and, in lieu of common stock to investor who so chose, pre-funded warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,380,956</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock in a follow-on offering, including </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">833,333</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock. The price to the public of the shares of common stock was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">63.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and the price to the public of the pre-funded warrants was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">62.9999</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per pre-funded warrant. The pre-funded warrants have an exercise price equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and do not expire. The pre-funded warrants were accounted for as equity instruments. The Company received total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">384.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 28, 2022, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8,563,830</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a price per share to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in a follow-on public offering including an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,117,021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock that were sold at the follow-on public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share pursuant to the underwriters’ </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">agreement in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of approximately</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">380.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for these transactions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 18, 2021, the Company issued and sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,062,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock at a price per share to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in a follow-on public offering including an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,312,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock that were sold at the follow-on public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share pursuant to the underwriters’ agreement in full exercise of their option to purchase additional shares of common stock. The Company received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">380.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and offering costs of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for these transactions.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity and Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. From inception to December 31, 2023, the Company has incurred cash outflows from operations, losses from operations, and had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> billion, primarily as a result of expenses incurred through a combination of research and development activities related to the Company’s various product candidates and expenses supporting those activities. The Company has primarily financed its operations through public offerings of its common stock, convertible debt, private placements of preferred stock prior to its initial public offering, the development funding agreement with SFJ, and the collaboration agreement with Sobi. The Company has financed a portion of its operations through product sales but has not yet achieved profitability.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company believes that its cash and cash equivalents of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">351.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at December 31, 2023 and the cash anticipated to be generated from the unwind of the capped call transactions, together with cash anticipated to be generated from sales of EMPAVELI and from SYFOVRE will be sufficient to fund its operations and capital expenditure requirements for at least twelve months from the date of issuance of these consolidated financial statements.</span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2800000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	351200000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:2.253%;text-indent:2.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Estimates are used in the following areas, among others: development liability, accrued expenses, prepaid expenses, convertible debt, reserves for variable consideration, reserves for excess or obsolete inventories, and income taxes.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	22408000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	36658000
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, and marketable securities. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and the issuers of its cash equivalents and marketable securities. The Company maintains its cash, cash equivalents and marketable securities with highly-rated, federally-insured financial institutions. At times, such amounts may exceed federally-insured limits. The Company has not experienced any losses on its deposits since inception, and management believes that minimal credit risk exists with respect to these financial institutions.</span></p>
CY2023	apls	Maximum Number Of Employees With Employers Eligible For Refundable Tax Credit MaximumNumberOfEmployeesWithEmployersEligibleForRefundableTaxCredit	500
CY2021	apls	Percentage Of Qualified Wages Paid To Employees Under Employee Retention Credit PercentageOfQualifiedWagesPaidToEmployeesUnderEmployeeRetentionCredit	0.70
CY2021Q3	apls	Maximum Credit Per Employee For Each Calendar Quarter MaximumCreditPerEmployeeForEachCalendarQuarter	7000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	206400000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7700000
CY2022Q4	apls	Refund Filed Under Cares Act Relating To Employee Retention Credit RefundFiledUnderCaresActRelatingToEmployeeRetentionCredit	8700000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	520000
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	32724000
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	29847000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	82924000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	54101000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	30714000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1766000
CY2023Q4	us-gaap	Inventory Net InventoryNet	146362000
CY2022Q4	us-gaap	Inventory Net InventoryNet	85714000
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	6400000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	1500000
CY2023Q4	apls	Down Payments For Inventory Current DownPaymentsForInventoryCurrent	16296000
CY2022Q4	apls	Down Payments For Inventory Current DownPaymentsForInventoryCurrent	13987000
CY2023Q4	apls	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	13931000
CY2022Q4	apls	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	15181000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8593000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	7182000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38820000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36350000
CY2023Q4	apls	Royalties Receivable Current RoyaltiesReceivableCurrent	3054000
CY2022Q4	apls	Royalties Receivable Current RoyaltiesReceivableCurrent	1442000
CY2022Q4	apls	Employee Retention Credit Current EmployeeRetentionCreditCurrent	8711000
CY2023Q4	apls	Receivable From Collaboration Agreement Current ReceivableFromCollaborationAgreementCurrent	15000000
CY2022Q4	apls	Receivable From Collaboration Agreement Current ReceivableFromCollaborationAgreementCurrent	20000000
CY2023Q4	apls	Deposits And Other Current Assets DepositsAndOtherCurrentAssets	4354000
CY2022Q4	apls	Deposits And Other Current Assets DepositsAndOtherCurrentAssets	6505000
CY2023Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	28318000
CY2022Q4	apls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	34849000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10197000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	907000
CY2023Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	51781000
CY2022Q4	apls	Accrued Payroll Liabilities Current AccruedPayrollLiabilitiesCurrent	43212000
CY2023Q4	apls	Product Revenue Reserves Current ProductRevenueReservesCurrent	16625000
CY2022Q4	apls	Product Revenue Reserves Current ProductRevenueReservesCurrent	2351000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20885000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13820000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	127806000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95139000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	297000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	459000
CY2023	apls	Contractual Interest Expense ContractualInterestExpense	3286000
CY2022	apls	Contractual Interest Expense ContractualInterestExpense	5248000
CY2021	apls	Contractual Interest Expense ContractualInterestExpense	11086000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	3583000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	5707000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	12050000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3286000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3286000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	96225000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	102797000
CY2023Q4	us-gaap	Longterm Debt Percentage Bearing Fixed Interest Amount LongtermDebtPercentageBearingFixedInterestAmount	8900000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	864000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	93033000
CY2023	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company enters into lease agreements with terms generally ranging from 2-7 years. Some of the Company’s lease agreements include Company options to extend the lease on a month-to-month basis or for set periods for up to five years. Many leases also include options to terminate the leases within one year or per other contractual terms. Renewal and termination options were generally not included in the lease term for the Company’s existing operating leases.
CY2023	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2023	apls	Lessee Operating Lease Maximum Term Of Options To Terminate Lease LesseeOperatingLeaseMaximumTermOfOptionsToTerminateLease	P1Y
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16745000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18747000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17895000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	19977000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M25D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0726
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7000000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	6200000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5600000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	7939000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	7375000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	5989000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2700000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5675000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7393000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6238000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5299000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	859000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	19789000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1894000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17895000
CY2023	apls	Defined Contribution Plan Eligibility Criteria Minimum Age Of Full Time Employees DefinedContributionPlanEligibilityCriteriaMinimumAgeOfFullTimeEmployees	P21Y
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5700000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4300000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3100000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48495000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-82815000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-314673000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-478001000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-568688000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-431329000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-526496000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-651503000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-746002000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1869000
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	149000
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	147000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2132000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	669000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	352000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2132000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	669000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-110564000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-136816000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-156660000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	42100000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.08
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	50219000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.077
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	38677000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.052
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-13438000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	9051000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.014
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-14145000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.019
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	119592000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.232
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	94668000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.145
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	133668000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.179
CY2023	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	11566000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.022
CY2022	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	19966000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	20005000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.026
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-26881000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.051
CY2022	apls	Tax Cuts And Jobs Act Of2017 Change In State Apportionment TaxCutsAndJobsActOf2017ChangeInStateApportionment	-35000
CY2022	apls	Income Tax Reconciliation Loss On Debt Conversion IncomeTaxReconciliationLossOnDebtConversion	-6626000
CY2022	apls	Effective Income Tax Rate Reconciliation Loss On Debt Conversion EffectiveIncomeTaxRateReconciliationLossOnDebtConversion	-0.01
CY2021	apls	Income Tax Reconciliation Loss On Debt Conversion IncomeTaxReconciliationLossOnDebtConversion	-19548000
CY2021	apls	Effective Income Tax Rate Reconciliation Loss On Debt Conversion EffectiveIncomeTaxRateReconciliationLossOnDebtConversion	-0.026
CY2023	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	2889000
CY2023	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	-0.001
CY2022	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	-3078000
CY2022	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	0.005
CY2021	apls	Income Tax Reconciliation Change In Permanent And Other IncomeTaxReconciliationChangeInPermanentAndOther	-731000
CY2021	apls	Effective Income Tax Rate Reconciliation Permanent And Other EffectiveIncomeTaxRateReconciliationPermanentAndOther	0.001
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2132000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	669000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	352000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	192444000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	187839000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	31712000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	29673000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	329135000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	228985000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	67667000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	57419000
CY2023Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	34023000
CY2022Q4	apls	Deferred Tax Assets Orphan Drug Credits DeferredTaxAssetsOrphanDrugCredits	30160000
CY2023Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	75190000
CY2022Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	79374000
CY2023Q4	apls	Deferred Tax Assets Convertible Debt DeferredTaxAssetsConvertibleDebt	5582000
CY2022Q4	apls	Deferred Tax Assets Convertible Debt DeferredTaxAssetsConvertibleDebt	6850000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	18000
CY2023Q4	apls	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	2888000
CY2022Q4	apls	Deferred Tax Asset Lease Liability DeferredTaxAssetLeaseLiability	4304000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	17401000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	16272000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	756060000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	640876000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	91000
CY2023Q4	apls	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	2672000
CY2022Q4	apls	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	4032000
CY2022Q4	apls	Deferred Tax Liabilities Section481 A Adjustment DeferredTaxLiabilitiesSection481AAdjustment	233000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2672000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4356000
CY2023Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	753388000
CY2022Q4	apls	Net Deferred Tax Assets Before Valuation Allowance NetDeferredTaxAssetsBeforeValuationAllowance	636520000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	753388000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	636520000
CY2023	apls	Capitalization Of Research And Development Costs CapitalizationOfResearchAndDevelopmentCosts	42300000
CY2022	apls	Capitalization Of Research And Development Costs CapitalizationOfResearchAndDevelopmentCosts	47600000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	116900000
CY2023	apls	Net Operating Loss Carryforward Period NetOperatingLossCarryforwardPeriod	P3Y
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Generally, the tax years 2020 through 2022 remain open and subject to examination by the major taxing jurisdictions to which the Company is subject.
CY2023	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	0
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19180000
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16793000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13576000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105945000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	91085000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	70667000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P48M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	Options granted to employees on or after December 5, 2013 generally vest in installments of (i) 25% at the one-year anniversary and (ii) in either 36 equal monthly or 12 equal quarterly installments beginning in the thirteenth month after the initial vesting commencement date (as defined) subject to the employee’s continuous service with the Company.
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12295000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.31
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	317031000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	838000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	52.48
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3950000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.11
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	519000
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	43.65
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8664000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.65
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6712000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.2
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M20D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	226419000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1952000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	45.97
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	27515000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	800000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2700000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	34.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.62
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.72
CY2023Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	181000000
CY2022Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	44800000
CY2021Q4	apls	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodAggregateIntrinsicValue	39900000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	46800000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	59000000
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	53200000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	46100000
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M4D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.035
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0401
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0115
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0337
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0041
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0134
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.684
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.683
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.704
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.717
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.744
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-528628000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-652172000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-746354000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	118678000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	118678000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106114000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106114000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84421000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84421000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.45
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.45
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.15
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.84
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.84
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15344000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18246000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18651000
CY2023	dei	Auditor Firm AuditorFirmId	34

Files In Submission

Name	View Source	Status
0000950170-24-020614-index-headers.html	Edgar Link	pending
0000950170-24-020614-index.html	Edgar Link	pending
0000950170-24-020614.txt	Edgar Link	pending
0000950170-24-020614-xbrl.zip	Edgar Link	pending
apls-20231231.htm	Edgar Link	pending
apls-20231231.xsd	Edgar Link	pending
apls-ex10_28.htm	Edgar Link	pending
apls-ex21_1.htm	Edgar Link	pending
apls-ex23_1.htm	Edgar Link	pending
apls-ex31_1.htm	Edgar Link	pending
apls-ex31_2.htm	Edgar Link	pending
apls-ex32_1.htm	Edgar Link	pending
apls-ex32_2.htm	Edgar Link	pending
apls-ex97_1.htm	Edgar Link	pending
apls-ex97_1.pdf	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img114409135_0.jpg	Edgar Link	pending
img138179509_0.jpg	Edgar Link	pending
img138179509_1.jpg	Edgar Link	pending
img138179509_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
apls-20231231_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls

2024 Q1 Form 10-K Financial Statement

#000095017024020614 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS Apellis Pharmaceuticals, Inc. Stock $apls

2024 Q1 Form 10-K Financial Statement

#000095017024020614 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APLS
Apellis Pharmaceuticals, Inc. Stock $apls